StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) operating KPIs

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)

Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%

Gilead Sciences total HCV Franchise (legacy sub-franchise breakout) ($M) ($M)

Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary

QuarterlyAnnual
Latest, FY2023
1,767
Period ended Dec 31, 2023
Change on a year earlier
-2.4%
1,810 in FY2022
History
6 years
Since FY2018
Sources
4
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal HCV Franchise (legacy sub-franchise breakout) ($M) ($M)Year on yearSource
FY2023Dec 31, 20231,767-2.4%Form 10-K (filed 2024-02-23) ↗
FY2022Dec 31, 20221,810-3.8%Form 10-K (filed 2024-02-23) ↗
FY2021Dec 31, 20211,881-8.9%Form 10-K (filed 2024-02-23) ↗
FY2020Dec 31, 20202,064-29.7%Form 10-K (filed 2023-02-22) ↗
FY2019Dec 31, 20192,936-20.3%Form 10-K (filed 2022-02-23) ↗
FY2018Dec 31, 20183,686–Form 10-K (filed 2021-02-25) ↗

Breakdown

What makes up total hcv franchise (legacy sub-franchise breakout) ($m)

Cite this data

StockData. (2026). Gilead Sciences Total HCV Franchise (legacy sub-franchise breakout) ($M) ($M), annual FY2018–FY2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver_hcv_total

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.